What Is Urolithin A

Urolithin A is a metabolite generated when specific gut bacteria break down ellagitannins, polyphenols found in pomegranates, walnuts, and some berries. Its primary biological function is triggering mitophagy, the targeted degradation and recycling of damaged mitochondria within cells. Because not everyone's gut microbiome can produce it efficiently, urolithin A has been developed as a direct oral supplement.

Mitochondria deteriorate with age. As damaged mitochondria accumulate inside cells, they produce less ATP and generate more reactive oxygen species, contributing to the cellular dysfunction that underlies age-related decline in muscle, brain, and cardiovascular tissues. Mitophagy is the cell's built-in quality control system for addressing this problem, but its efficiency drops as organisms age.

Urolithin A matters for longevity because it reactivates this declining quality control process. By clearing dysfunctional mitochondria and allowing cells to regenerate healthier ones, it addresses one of the root mechanisms of biological aging rather than merely suppressing a symptom. The compound sits at an intersection of nutrition, microbiome science, and mitochondrial biology, making it a focal point for researchers studying how metabolic function can be maintained across the lifespan.

When a person consumes foods containing ellagitannins, gut bacteria from the Gordonibacter and Ellagibacter genera hydrolyze these polyphenols through a series of steps. The final product of this microbial metabolism is urolithin A, which is absorbed through the intestinal wall and enters systemic circulation. Once inside cells, urolithin A activates a signaling cascade involving the PINK1/Parkin pathway, the same molecular machinery cells use to tag damaged mitochondria for degradation via autophagosomes.

The tagged mitochondria are enclosed in double-membrane vesicles and delivered to lysosomes, where they are broken down and their components recycled. This process, called mitophagy, frees up cellular resources and removes organelles that would otherwise leak electrons and generate oxidative damage. With dysfunctional mitochondria cleared, cells upregulate mitochondrial biogenesis, the creation of new, intact mitochondria, partly through activation of PGC-1 alpha and related transcription factors.

Beyond mitophagy, urolithin A has demonstrated anti-inflammatory properties in preclinical models, reducing NF-kB signaling and lowering circulating levels of inflammatory cytokines. It also appears to improve muscle stem cell function in aged animals, suggesting effects on tissue regeneration that extend beyond simple energy metabolism. These parallel mechanisms may explain why clinical trials have observed improvements in both muscle endurance and systemic inflammatory markers.

Urolithin A is available primarily as an oral supplement in soft gel capsules and powder sachets. The most commercially recognized form is Mitopure, a proprietary synthetic urolithin A produced through a controlled fermentation process that does not depend on gut bacterial conversion. This synthetic form is bioidentical to the metabolite produced naturally in the gut.

Some products combine urolithin A with pomegranate extract or other polyphenol blends, though the rationale for this pairing is unclear given that the supplement already provides the end metabolite. The powder form can be mixed into food or beverages, which may improve adherence for those who dislike capsules. Topical formulations have been explored in preclinical skin-aging research, but oral delivery remains the only form with published clinical evidence for systemic mitophagy activation.

Published clinical trials have tested urolithin A at daily doses of 250 mg, 500 mg, and 1,000 mg. Biomarker improvements in mitochondrial function have been observed across this range, with 500 mg and 1,000 mg showing the most consistent effects. There is currently no established evidence that exceeding 1,000 mg daily provides additional benefit.

The compound is typically taken once daily with a meal. Fat-containing meals may modestly improve absorption, as urolithin A is lipophilic. Because its effects depend on sustained mitophagy signaling rather than acute peaks, consistent daily intake is more important than precise timing. Individuals who produce urolithin A efficiently from dietary sources may experience redundancy when supplementing, though there is no validated consumer-level test to determine one's natural production capacity with high precision.

When evaluating urolithin A supplements, look for products that specify the form and purity of urolithin A used, ideally with a certificate of analysis available from an independent third-party testing laboratory. The compound should be listed by its chemical identity (urolithin A or 3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one) rather than vaguely as "pomegranate metabolite blend."

Third-party certifications such as NSF International, Informed Sport, or USP Verified provide additional assurance of identity, potency, and absence of contaminants including heavy metals and microbial contamination. The manufacturing process matters as well: products made via controlled biofermentation or chemical synthesis with pharmaceutical-grade standards tend to deliver more consistent dosing than those derived from crude botanical extracts. Avoid products that list urolithin A only as part of a proprietary blend without disclosing the specific milligram amount per serving.

Human evidence for urolithin A is still developing but has reached a notable threshold. Several randomized, double-blind, placebo-controlled trials have been conducted in middle-aged and older adults, using doses of 250 mg to 1,000 mg daily over periods of one to four months. These trials have consistently shown improvements in plasma acylcarnitine profiles (a biomarker of mitochondrial function), reductions in inflammatory markers such as CRP and specific cytokines, and improvements in muscle endurance metrics like the six-minute walk test. One key trial demonstrated that urolithin A supplementation in sedentary older adults improved mitochondrial biomarkers to levels more consistent with younger, active individuals.

Animal research provides additional mechanistic support. Studies in aged mice and the nematode C. elegans have shown that urolithin A extends lifespan, improves exercise capacity, and enhances muscle stem cell function. However, lifespan extension in simple organisms does not reliably translate to humans. The existing clinical trials, while well-designed, are relatively small (typically fewer than 100 participants) and short in duration. Longer-term outcomes, optimal dosing across diverse populations, and effects in individuals with specific diseases remain open questions. No head-to-head comparisons with other mitophagy-enhancing strategies have been published.

Urolithin A has shown a favorable safety profile in published trials, with gastrointestinal discomfort as the most commonly reported side effect. No serious adverse events have been attributed to the compound at studied doses. That said, long-term safety data beyond four months of continuous use is lacking. Individuals taking medications metabolized by cytochrome P450 enzymes should be aware that interactions have not been thoroughly characterized. Pregnant or nursing individuals and those with significant kidney or liver impairment lack specific safety data for this compound.